a 002

ATX-002 is a property-tunable lipid for RNA drug delivery.

ZLc-002 is a selective small-molecule inhibitor of nNOS-Capon coupling. ZLc-002 suppresses inflammatory nociception and chemotherapy-induced neuropathic pain. ZLc-002 can be used in anxiety disorder and inflammation research[1] [2] [3].

(Rac)-ZLc-002 is a compound that inhibits the interaction between neuronal nitric oxide synthase (nNOS) and the nitric oxide synthase 1 adaptor protein (NOS1AP), effectively reducing inflammatory pain and chemotherapy-induced neuropathic discomfort. Additionally, it enhances the efficacy of Paclitaxel in decreasing tumor cell viability [1] [2].

IST5-002 is a potent inhibitor of Stat5a/b and selectively inhibits the transcriptional activity of Stat5a/b with IC50 values of 1.5 μM and 3.5 μM for Stat5a and Stat5b, respectively. IST5-002 can be used to study prostate cancer and chronic granulocytic leukaemia (CML).

PH-002, an inhibitor targeting the intramolecular domain interaction of apolipoprotein (apo) E4 in neuronal cells, additionally enhances mitochondrial motility and promotes neurite outgrowth, thereby countering related impairments.

Varespladib methyl (LY333013), a bioavailable prodrug of Varespladib, is a selective group II secretory phospholipase A2 inhibitor.

WDB002, a natural product belonging to the FK506/rapamycin family, targets CEP250 and may be employed in COVID-19 research [1].

LU-002i is a selective inhibitor targeting the human proteasome subunits β2c and β2i, demonstrating an inhibitory concentration (IC50) of 220 nM for β2i [1].

The S-enantiomer of BET-BAY 002, referred to as BET-BAY 002 S enantiomer, is a potent inhibitor of BET (Bromodomain and Extra-Terminal motif proteins).

BET-BAY 002 is an effective BET inhibitor and exhibits efficacy in a multiple myeloma model.

OG-L002 is an effective and selective LSD1 inhibitor (IC50: 20 nM), showing 69- and 36-fold selectivity over MAO-A and MAO-B, respectively.

MIR002 is a potent, orally active dual inhibitor of DNA polymerase α (POLA1) and HDAC 11 with significant in vivo antitumor activity. p53 acetylation, p21 activation, cell cycle arrest in G1/S phase, and apoptosis induction.

L002, a potent, cell-permeable, reversible, and specific acetyltransferase p300 (KAT3B) inhibitor with an IC50 of 1.98 μM, directly binds the acetyl-CoA pocket and competitively inhibits the FATp300 catalytic domain. By blocking histone acetylation, p53 acetylation, and STAT3 activation, L002 shows potential in the treatment of hypertension‐induced cardiac hypertrophy and fibrogenesis.

JT002 is an orally active NLRP3 inflammasome inhibitor that decreases the production of NLRP3-dependent proinflammatory cytokines (such as IL-1β, IL-1α, IL-18) and pyroptosis, as well as inhibits the formation of the NLRP3 inflammasome complex. Additionally, JT002 mitigates airway hyperresponsiveness and airway neutrophilia in mice [1].

JB002, a myosin II inhibitor, exhibits potent activity with an IC50 of ≤10 μM. It holds potential for research applications in muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy.

Compound N002-0015 is a useful organic compound for research related to life sciences and the catalog number is T131387.

Enoblituzumab is a humanized IgG1 κmab monoclonal antibody that recognizes human B7-H3 protein and can be used to study solid tumors such as non-small cell lung cancer (NSCLC).

Compound N002-0035 is a useful organic compound for research related to life sciences and the catalog number is T131384.

Compound N002-0024 is a useful organic compound for research related to life sciences and the catalog number is T131386.

Compound N002-0028 is a useful organic compound for research related to life sciences and the catalog number is T131385.

B-002 is CB (cannabinoid) receptor ligand that governs the cannabimimetic potency.

IBPR002 is an aurora kinase inhibitor which reveals mechanisms of HURP in nucleation of centrosomal and kinetochore microtubules.

Triciribine phosphate (VD 002) is a highly selective AKT inhibitor that induces cell cycle arrest and cysteinyl asparagin-dependent apoptosis, inhibits neovascularization, and can be used in the study of leukemia.

Ralaniten (EPI-002) is a potent, specific, and orally active antagonist of the androgen receptor N-terminal structural domain (AR-NTD).Ralaniten inhibits AR transcriptional activity with an IC50 value of 7.4 μM.Ralanites have anticancer activity and can be used to study desmoplasia-resistant prostate cancer (CRPC).

α-MSH (MSH, amide) is amide stimulates melanocortin 1 receptor that results in the activation of adenylyl cyclase.

PRMT5-IN-18 (Compound 002) is a potent inhibitor of PRMT5 and can be used in the study of PRMT5-mediated diseases, such as tumours.

Gusacitinib, also known as ASN-002 and EN-3351, is a potent dual inhibitor of SYK/JAK kinases. ASN002 showed strong antitumor activity in both hematological and solid tumor xenograft models. ASN002 strongly suppressed the SYK and JAK family kinase signaling pathways as measured in pLAT and pSTAT assays, respectively. When profiled in a panel of 178 cell lines, ASN002 showed strong anti-proliferative activity in many lymphoid/leukemia cell lines, including SU-DHL-6, SU-DHL-4, OCI-LY10, H929 and Pfeiffer.

Zapnometinib (ATR-002) is a MEK inhibitor.

SC209, an ADC cytotoxin is used in synthesis of anti- EGFR antibody-drug conjugate ADC. SC209 is a metabolite of STRO-002 [1] [2] .

Quisovalimab (AVTX-002; AEVI 002; SAR 252067), a human monoclonal antibody targeting LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14), is crucial for managing acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) in COVID-19. This compound has potential applications in treating ARDS related to COVID-19 and is subject to ongoing research [1].

Cantrixil (TRX-E-002-1) is a second-generation super-benzopyran (SBP) compound, derived from TRX-E-002. It elicits an increase in phosphorylated c-Jun levels, leading to caspase-mediated apoptosis in ovarian cancer cells. Cantrixil exhibits potent pan anti-cancer activity against various cancer phenotypes.

Prasinezumab (PRX 002), a humanized IgG1 monoclonal antibody targeting aggregated α-synuclein, shows promise for Parkinson's disease research [1].

20-HEDE (WIT 002) is a 20-hydroxyeicosatetraenoic acid (20-HETE) antagonist.

8-M-PDOT (AH-002) is a selective and potent melatonin MT2 receptor agonist that also inhibits MT1 receptors.8-M-PDOT has anxiolytic activity and may be used to study MT2-induced neuropathic pain.